SEC Form 4 · accession 0000950142-15-000871
PERNIX THERAPEUTICS HOLDINGS, INC. · PTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steve Elms
Director
Period of report
Apr 22, 2015
Accepted (ET)
Apr 24, 2015 · 4:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001024126
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 2,000,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.25% Convertible Senior Notes due 2021F1,F2 | $11.47 | Apr 22, 2015 | P | 2,500,000 | A | Apr 22, 2015 | Apr 1, 2021 | Common Stock | 218,008 | 2,500,000 | I |
Explanation of responses
- F1The reportable securities are held directly by Aisling Capital III, LP, and are indirectly held by Aisling Capital LLC, as general partner of Aisling Capital III, LP and each of the individual managing members of Aisling Capital LLC, including the Reporting Person. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
- F2The Issuer's 4.25% Convertible Senior Notes due 2021 are convertible into 87.2030 shares of the Issuer's common stock per $1,000 principal amount of notes, subject to certain anti-dilution adjustments. Upon conversion, notes may be settled in cash or the Issuer's common stock at the option of the Issuer.